Study Protein-Protein Interactions Within Cells

Pharmacological Intervention to prevent proteins interacting with each other represent a novel approach for drug discovery. This poster describes how two proteins can be labelled such that when these proteins interact, the recombination of the labels results in a luminescence readout that translates into a fluorescence readout. A reduction in fluorescence in the presence of a compound indicates inhibition of the interaction. This interaction can be monitored in living cells allowing a phenotypic, arguably a more physiological readout. In our example Schnurri-3 interacts with ERK-2 to modulate bone density. By pharmacologically manipulating this interaction we could increase bone density for oesteoporetic patients.

Go to the profile of Gary Allenby
Oct 19, 2017
0
0
Go to the profile of Gary Allenby

Gary Allenby

Chief Scientific Officer, Aurelia Bioscience

Ph.D. in Reproductive Toxicology, post-doc at Hoffmann La Roche in U.S.A. working on retinoid (Vitamin A) biology, returned to UK to work at Glaxo Wellcome developing cell-based assay development for screening purposes then AstraZeneca. In 2011 I was one of the founding entrepreneurs of Aurelia Bioscience, a CRO in the UK. We develop bioassays for clients to test compounds and biologics.

No comments yet.